Our results demonstrated no statistically significant differences in OS and PFS between CD4 ≤200 and >200 groups for both HIV-affected and non-HIV-affected HL patients (all P>0.05) (Figure 5). This evidence concerns the gene CD4 and Hodgkins lymphoma.